Alterity Therapeutics Limited, a development stage enterprise, has announced the cessation of 12,000,000 options due to their expiry without exercise or conversion. The options, identified by the ASX security code ATHAAF and expiring on July 31, 2024, had an exercise price of $0.07. This event was officially reported in a Form 6-K filed with the SEC for the month of August 2024. Following the cessation of these securities, Alterity Therapeutics provided an update on its issued capital, which includes various classes of securities and options with different expiry dates and exercise prices. The company's ordinary fully paid shares total 5,320,336,118, and there are several other options with expiry dates ranging from August 2024 to March 2029. The cessation of the ATHAAF options has not involved any consideration from the entity.

Alterity Therapeutics Limited, a development stage enterprise, has announced the cessation of 12,000,000 options due to their expiry without exercise or conversion. The options, identified by the ASX security code ATHAAF and expiring on July 31, 2024, had an exercise price of $0.07. This event was officially reported in a Form 6-K filed with the SEC for the month of August 2024. Following the cessation of these securities, Alterity Therapeutics provided an update on its issued capital, which includes various classes of securities and options with different expiry dates and exercise prices. The company's ordinary fully paid shares total 5,320,336,118, and there are several other options with expiry dates ranging from August 2024 to March 2029. The cessation of the ATHAAF options has not involved any consideration from the entity.